Abstract Ransomware has become one of the most prevalent and dangerous cybersecurity threats, capable of encrypting critical files and demanding ransom payments within minutes of infection. A novel hybrid detection system is proposed that combines Isolation Forest for anomaly detection with XGBoost for classification, addressing the limitations of traditional signature-based approaches and enhancing early-stage detection capabilities. The system continuously monitors file system activities, extracting features indicative of ransomware behavior, and processes them through a machine learning pipeline designed to identify both known and novel ransomware variants in real-time. Experimental evaluation demonstrates that the system achieves high accuracy in detecting ransomware with minimal false positives and low detection latency, making it suitable for deployment in enterprise environments where rapid response is critical. The ability to handle large volumes of file system data while maintaining precision and adaptability highlights the system's scalability and robustness in combating evolving ransomware threats. This research significantly contributes to the field of cybersecurity, offering a practical and efficient approach for protecting Windows-based systems from ransomware attacks.
Recent studies have demonstrated mortality benefits from corticosteroid use in COVID-19 patients requiring respiratory support. However, clinical practice may warrant the use of corticosteroids outside the context of a clinical trial. Such data are rarely, if ever, reported. We explored the use of corticosteroids for adult respiratory distress syndrome (ARDS) indications in patients with non-COVID ARDS.We retrospectively studied patients with moderate-to-severe ARDS, admitted to our intensive care unit (ICU) between January 2018 and March 2020.Of the 91 patients with ARDS identified, 80% were treated with a corticosteroid during their ICU admission. Of these, 73 (82%) had corticosteroids administered for reasons other than ARDS.Corticosteroid use for non-ARDS indications is commonplace in ARDS patients in our ICU. The use of corticosteroids outside a randomisation process in randomised clinical trials may be more common than appreciated and needs to be routinely reported.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
